With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled

With data demonstrating superiority to Humira and likely lower pricing than anti-TNF drugs, baricitinib may be poised to make more of an impact than Pfizer has with its JAK inhibitor Xeljanz.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America